BLAINTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
24
Data completeness
5/8 — Partial
Priority Review
BESPONSA (inotuzumab ozogamicin) by Pfizer is cd22-directed antibody interactions [moa]. First approved in 2017.
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BESPONSA (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC) approved in 2017 for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It works by binding to CD22 on B cells and delivering a cytotoxic payload to kill malignant cells. The drug represents a targeted immunotherapy approach in a high-acuity oncology setting.
$0.002BPart D
PeakProduct is at peak lifecycle stage with modest Medicare utilization, suggesting stable commercial team size focused on maintenance and specialty pharmacy channel management.
Mechanism of Action
CD22-directed Antibody Interactions
Pharmacologic Class:
CD22-directed Immunoconjugate
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (24)
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
Started Nov 2024
12 enrolled
Acute Lymphocytic Leukemia
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Started May 2023
100 enrolled
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
Started Mar 2023
32 enrolled
Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Started Feb 2023
44 enrolled
Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Started Jan 2021
0Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more
Worked on BESPONSA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.